<?xml version="1.0" encoding="UTF-8"?><xmi:XMI xmlns:cas="http:///uima/cas.ecore" xmlns:xmi="http://www.omg.org/XMI" xmlns:type="http:///org/apache/uima/trials/type.ecore" xmlns:tcas="http:///uima/tcas.ecore" xmi:version="2.0">
    <cas:NULL xmi:id="0"/>
    <tcas:DocumentAnnotation xmi:id="1" sofa="6" begin="0" end="1573" language="x-unspecified"/>
    <type:PFSMean xmi:id="13" sofa="6" begin="800" end="803"/>
    <type:PFSMean xmi:id="29" sofa="6" begin="1273" end="1275"/>
    <type:PFSMean xmi:id="33" sofa="6" begin="1280" end="1288"/>
    <type:OSMean xmi:id="17" sofa="6" begin="808" end="819"/>
    <type:OSMean xmi:id="37" sofa="6" begin="1297" end="1299"/>
    <type:OSMean xmi:id="41" sofa="6" begin="1304" end="1313"/>
    <type:ORR xmi:id="21" sofa="6" begin="1248" end="1250"/>
    <type:ORR xmi:id="25" sofa="6" begin="1255" end="1257"/>
    <cas:Sofa xmi:id="6" sofaNum="1" sofaID="_InitialView" mimeType="text" sofaString="This phase II trial evaluated efficacy and safety of temozolomide (TMZ) in&#13;&#10;combination with irinotecan (CPT-11) before radiotherapy in patients with newly&#13;&#10;diagnosed glioblastoma multiforme (GBM). Prior to radiotherapy, patients were&#13;&#10;treated with a maximum of three 6-week cycles of TMZ and CPT-11. Patients&#13;&#10;received TMZ at a dose of 200 mg/m(2)/day on days 1-5 and CPT-11 on days 1, 8,&#13;&#10;22, and 29, with a dose adjustment for enzyme-inducing antiepileptic drug use.&#13;&#10;The primary end point was objective response rate (ORR). Secondary end points&#13;&#10;included progression-free survival (PFS), overall survival (OS), safety, and&#13;&#10;tumor O(6)-methylguanine-DNA methyltransferase (MGMT) expression. Of the 42&#13;&#10;patients treated, 8 (19%) patients achieved a partial response. Median PFS and&#13;&#10;median OS were 3.1 and 13.8 months, respectively. Grade 3 or 4 AEs were&#13;&#10;documented in 36% of patients, most of which were hematologic (29%). Twenty-four &#13;&#10;percent of patients had grade 3 or 4 non-hematologic AEs, with gastrointestinal&#13;&#10;AEs being the most common (12%) Two patients died, one of intracranial hemorrhage&#13;&#10;and one of treatment-related renal failure. Low MGMT expression, compared with&#13;&#10;high MGMT expression, showed no significant difference in ORR (25 vs. 8%), median&#13;&#10;PFS (14 vs. 5 months) or OS (21 vs. 15 months). Although TMZ plus CPT-11 is at&#13;&#10;least comparable in efficacy to TMZ alone, this combination appears more toxic&#13;&#10;and poorly tolerated. The lack of correlation of activity with MGMT expression is&#13;&#10;intriguing, but needs further evaluation in subsequent trials."/>
    <cas:View sofa="6" members="1 13 29 33 17 37 41 21 25"/>
</xmi:XMI>
